A share price of Foghorn Therapeutics Inc [FHTX] is currently trading at $4.81, up 2.56%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The FHTX shares have gain 8.82% over the last week, with a monthly amount glided 20.55%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Foghorn Therapeutics Inc [NASDAQ: FHTX] stock has seen the most recent analyst activity on November 07, 2025, when Guggenheim initiated its Buy rating and assigned the stock a price target of $12. On April 23, 2025, Citizens JMP initiated with a Mkt Outperform rating and assigned a price target of $9 on the stock. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $10 on January 30, 2025. Jefferies initiated its recommendation with a Buy and recommended $18 as its price target on September 03, 2024. Evercore ISI started tracking with an Outperform rating for this stock on August 19, 2024, and assigned it a price target of $20. In a note dated March 28, 2023, BofA Securities initiated a Buy rating and provided a target price of $10 on this stock.
Foghorn Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $2.94 and $8.79. Currently, Wall Street analysts expect the stock to reach $15.5 within the next 12 months. Foghorn Therapeutics Inc [NASDAQ: FHTX] shares were valued at $4.81 at the most recent close of the market. An investor can expect a potential return of 222.25% based on the average FHTX price forecast.
Analyzing the FHTX fundamentals
Trailing Twelve Months sales for Foghorn Therapeutics Inc [NASDAQ:FHTX] were 24.52M which represents 4.42% growth. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -3.8%, Pretax Profit Margin comes in at -3.12%, and Net Profit Margin reading is -3.12%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is 1.42 and Total Capital is -0.62. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.48 points at the first support level, and at 4.15 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.41, and for the 2nd resistance point, it is at 6.02.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Foghorn Therapeutics Inc [NASDAQ:FHTX] is 2.16. As well, the Quick Ratio is 2.16, while the Cash Ratio is 0.95. Considering the valuation of this stock, the price to sales ratio is 11.09.
